Skip to main content
. Author manuscript; available in PMC: 2011 Jan 24.
Published in final edited form as: J Clin Oncol. 2008 Feb 20;26(6):934–941. doi: 10.1200/JCO.2007.12.3414

Table 3.

Bivariate Associations of Patient Characteristics With PTSD Symptoms (PCL-C Score)

No. of
Patients
PCL-C
Score
Correlation
(r)
Characteristic Mean SD P*
Demographics
 Sex
  Male 429 26.8 9.9 .511
  Female 439 27.2 9.9
 Race
  White 745 26.4 9.1 Ref, < .001*
  African American 85 29.1 12.8 .064
  American Indian 3 34.7 6.5 .118
  Asian 2 32.5 13.4 .347
  Mixed Race 30 33.8 13.1 .005
  Other 3 43.3 21.9 .313
 Ethnicity
  Hispanic 13 31.9 15.7 .276
  Non-Hispanic 855 27.0 9.8
 Income −0.148 < .001
  < $30,000 217 29.6 11.4 Ref, < .001*
  $30,000-$59,999 238 26.6 9.8 .003
  $60,000-$89,999 138 26.5 9.5 .006
  ≥ $90,000 189 25.3 8.0 < .001
 Education −0.110 .001
  High school or less 243 28.9 11.1 < .001
  Some college or
   trade school
276 27.2 10.4 .017
  College or more 333 25.4 7.9 Ref, < .001*
 Marital status
  Married 642 26.8 9.8 Ref, .095*
  Living with partner 24 29.0 9.3 .277
  Widowed 88 26.7 9.3 .915
  Separated 5 37.4 11.2 .017
  Divorced 43 26.5 7.8 .851
  Single 63 28.9 12.2 .184
 Employment status
  Employed 346 26.4 8.9 Ref, .117*
  Unemployed 43 29.6 12.2 .106
  Retired 466 27.1 10.1 .300
 Age at enrollment,
  years
−0.145 < .001
  25-49 152 29.1 11.5 Ref, < .001*
  50-64 317 27.8 10.2 .221
  65-79 311 25.9 8.8 .003
  80+ 88 24.6 8.4 .001
Clinical characteristics
  for NHL
 Histology
  Aggressive 384 26.7 9.6 .491
  Indolent 437 27.2 10.2
 Stage at diagnosis 0.106 .004
  I 244 25.4 8.6 Ref, .015*
  II 153 27.4 9.1 .027
  III 145 28.0 10.3 .008
  IV 212 28.0 10.9 .006
 Total No. of treatment
   types ever
0.128 < .001
  0 35 27.0 12.2 Ref, < .001*
  1 216 26.2 9.1 .655
  2 338 26.1 8.8 .581
  3 192 27.4 10.1 .840
  4 65 31.1 12.4 .118
  5 19 34.1 15.5 .072
  6 2 28.0 4.2 .912
 Surgery
  Yes 245 27.8 10.5 .188
  No 599 26.8 9.7
 Radiation therapy
  Yes 415 27.1 10.3 .937
  No 453 27.0 9.6
 Chemotherapy
  Yes 685 27.3 9.9 .100
  No 183 26.0 10.0
 Bone marrow or stem-
   cell transplantation
  Yes 131 30.9 12.8 < .001
  No 737 26.3 9.1
 Biologic treatment
  Yes 260 28.4 10.9 .010
  No 608 26.5 9.4
 Current treatment
  Yes 116 29.1 10.2 .012
  No 743 26.6 9.7
 Active disease
  Yes 107 30.5 12.1 .001
  No 675 26.1 9.0
 Recurrence(s)
  Yes 291 28.5 10.8 .002
  No 554 26.2 9.4
 Frequency of visits 0.193 < .001
  0 167 24.6 8.2 Ref, < .001*
  1-2 125 26.0 9.1 .185
  3-4 137 26.5 9.6 .063
  5-6 129 26.4 8.4 .066
  7-10 89 28.6 10.9 .001
  11-20 85 28.9 10.6 < .001
  > 20 112 30.8 12.4 < .001
 Site of treatment
  Duke University 735 26.8 9.6 .063
  UNC 133 28.5 11.1
 Age at diagnosis,
  years
−0.083 .015
 Time since diagnosis,
  years
−0.108 .001
Health status
 Comorbidity score, 0-36 0.273 < .001
 Time since last
   physical exam,
   years
0.085 .013
 Secondary cancer
  Yes 119 27.0 9.3 .989
  No 743 27.0 10.0
Psychosocial
 Social support score,
   20-100
−0.355 < .001
 Appraisal of life threat
   and treatment
   intensity score, 6-30
0.369 < .001
 Insurance and
   employment issues
   related to cancer
   score, 0-24
0.274 < .001

Abbreviations: PTSD, post-traumatic stress disorder; PCL-C, PTSD Checklist–Civilian Version; SD, standard deviation; NHL, non-Hodgkin’s lymphoma; UNC, University of North Carolina.

*

P values are for the overall F-test for the categorical variable with k – 1 df, where k is the number of categories.